Key result
Large multicenter study tests PFO closure versus medical therapy for recurrent stroke in patients aged ≥60.
Why the study?
Randomized trials of percutaneous PFO closure for cryptogenic stroke have nearly all excluded individuals aged ≥60 years, leaving a critical evidence gap and variable clinical practice in older adults where competing stroke mechanisms are prevalent.
Does percutaneous patent foramen ovale closure reduce the risk of recurrent ischemic stroke compared with medical therapy in patients aged ≥60 years with cryptogenic stroke and a confirmed PFO?
Cohort
Yes
Does percutaneous patent foramen ovale closure reduce the risk of recurrent ischemic stroke compared with medical therapy in patients aged ≥60 years with cryptogenic stroke and a confirmed PFO?
Answers are grounded in this paper and cite their sources.
This study protocol outlines a large international multicenter retrospective cohort designed to address the critical evidence gap regarding the safety and effectiveness of PFO closure versus medical therapy in patients aged 60 years and older with cryptogenic stroke.
Background Patent foramen ovale (PFO) is a common cardiac abnormality associated with paradoxical embolism and ischemic stroke. Randomized trials have demonstrated the benefit of percutaneous PFO closure in patients aged <60 years with cryptogenic stroke, but nearly all trials have excluded individuals aged ≥60 years, leaving a critical evidence gap in older populations, in whom competing stroke mechanisms are prevalent. There is currently no dedicated, validated framework to guide closure decisions in this age group. Consequently, clinical practice remains highly variable, and closure decisions are made based on extrapolation from younger cohorts rather than robust evidence. Objective This study aims to evaluate the effectiveness and safety of PFO closure compared with medical therapy in patients aged ≥60 years with cryptogenic stroke and a confirmed PFO. Methods This multicenter international retrospective cohort study will include consecutive patients aged ≥60 years with imaging-confirmed ischemic stroke, a confirmed PFO, and no alternative definite etiology of stroke after standard diagnostic evaluation, who underwent either percutaneous PFO closure or medical therapy between 2015 and 2025. Outcomes will be collected through standardized chart review and entered into a centralized REDCap database. The primary outcome will be the risk of recurrent ischemic stroke. Secondary outcomes will include major bleeding, new-onset atrial fibrillation, device-related complications, and mortality. Time-to-event analyses, Cox regression, and propensity score methods will be used to adjust for confounding. Results As of October 2026, 51 centers from 10 countries (Argentina, Brazil, Colombia, Greece, Italy, Japan, Mexico, Portugal, Spain, and the United States) have formally agreed to participate in the study. Each site is currently in the process of securing institutional review board (IRB) approval and executing data use agreements. A standardized variable dictionary has been distributed to all centers to ensure consistency in data collection. As of October 2026, 45 centers have applied for local IRB approval, 5 centers have obtained IRB approval, and 3 centers have begun data entry into REDCap. The projected end date of data collection is June 2027. Participating centers are encouraged to propose independent research questions leveraging the pooled dataset. As of October 2026, 23 project titles have been submitted by investigators. These proposals will be evaluated once sufficient data have been accrued. Preliminary pooled analyses are anticipated for release in July 2027. Conclusions The PFO-COPA (Patent Foramen Ovale Closure Outcomes in Patients of Advanced Age) study will generate the most comprehensive real-world evidence to date on PFO closure in adults aged ≥60 years. By evaluating both effectiveness and safety in this understudied age group, the study will fill a major evidence gap and help guide clinical decision-making. Ultimately, these findings may inform future guideline updates and lay the groundwork for prospective multicenter trials focused specifically on older adults.
No takes yet. Share an insight, caveat, or question.
Jazayeri et al. (2026) conducted a cohort in Cryptogenic ischemic stroke with confirmed patent foramen ovale (PFO). Percutaneous patent foramen ovale (PFO) closure vs. Medical therapy was evaluated on Recurrent ischemic stroke. Percutaneous PFO closure versus medical therapy is being evaluated for recurrent stroke in patients aged ≥60 years across 51 centers in 10 countries (protocol; results anticipated July 2027).
Synapse has enriched 10 related papers. Consider them for comparative context: